Drug Profile
PG 4336
Latest Information Update: 02 Sep 1996
Price :
$50
*
At a glance
- Originator Pharmagenesis
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Aug 1996 Discontinued-Preclinical for Cancer in USA (unspecified route)